Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia
| Autor: | Alice Maltret, Anne Messali, Pascale Guicheney, Joël Kamblock, Joël Lunardi, Antoine Leenhardt, Fabrice Extramiana, Meiso Hayashi, Elisabeth Villain, Didier Klug, Seiji Takatsuki, Nathalie Roux Buisson, Isabelle Denjoy, Jean Marc Lupoglazoff, Miyuki Hayashi |
|---|---|
| Přispěvatelé: | Service de Cardiologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Biomarqueurs CArdioNeuroVASCulaires (BioCANVAS), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de cardiologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de Biochimie et Génétique Moléculaire, CHU Grenoble, Unité de Cardiologie Néonatale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré, Service de Cardiologie A, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de Cardiologie du Taaone, Physiopathologie et thérapie du muscle strié, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR14-Institut National de la Santé et de la Recherche Médicale (INSERM), The authors received a grant from the French national government named Programme Hospitalier de Recherche Clinique No. AOR04070, P040411., Roux-Buisson, Nathalie, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Lariboisière-Université Paris Diderot - Paris 7 ( UPD7 ), Biomarqueurs CArdioNeuroVASCulaires ( BioCANVAS ), Université Paris 13 ( UP13 ) -Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Robert Debré, Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -IFR14-Institut National de la Santé et de la Recherche Médicale ( INSERM ) |
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Male
Heart disease Ventricular tachycardia tachycardia MESH: Ryanodine Receptor Calcium Release Channel 0302 clinical medicine MESH : Child MESH: Child MESH: Incidence Child MESH: Middle Aged Incidence Hazard ratio MESH: Follow-Up Studies MESH : Incidence 3. Good health ventricular MESH: Young Adult Child Preschool beta-blocker Cardiology and Cardiovascular Medicine medicine.medical_specialty MESH : Young Adult MESH : Syncope Syncope 03 medical and health sciences [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system MESH : Adolescent Physiology (medical) death MESH: Polymorphism Genetic MESH: Calsequestrin Humans MESH : Middle Aged Risk factor Beta blocker sudden MESH: Adolescent Polymorphism Genetic MESH: Humans MESH : Humans MESH: Child Preschool MESH : Follow-Up Studies MESH: Adult medicine.disease Death Sudden Cardiac MESH: Family Health MESH: Tachycardia Ventricular mutation MESH: Exercise Test MESH: Female clinical genetics Tachycardia MESH : Polymorphism Genetic Kaplan-Meier Estimate MESH : Child Preschool 030204 cardiovascular system & hematology Sudden cardiac death Risk Factors MESH: Risk Factors MESH : Female 030212 general & internal medicine MESH: Kaplan-Meiers Estimate MESH : Ryanodine Receptor Calcium Release Channel MESH: Adrenergic beta-Antagonists Middle Aged MESH : Adult [ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system MESH : Calsequestrin MESH : Risk Factors follow-up studies [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system Cardiology Female medicine.symptom Adult Adolescent medicine.drug_class MESH : Male Adrenergic beta-Antagonists MESH : Adrenergic beta-Antagonists MESH : Tachycardia Ventricular MESH : Family Health Catecholaminergic polymorphic ventricular tachycardia Young Adult Internal medicine medicine Calsequestrin Family Health business.industry Ryanodine Receptor Calcium Release Channel MESH : Kaplan-Meiers Estimate MESH: Death Sudden Cardiac MESH: Male MESH : Exercise Test MESH: Syncope Exercise Test Tachycardia Ventricular business MESH : Death Sudden Cardiac |
| Zdroj: | Circulation Circulation, 2009, 119 (18), pp.2426-34. ⟨10.1161/CIRCULATIONAHA.108.829267⟩ Circulation, American Heart Association, 2009, 119 (18), pp.2426-34. ⟨10.1161/CIRCULATIONAHA.108.829267⟩ Circulation, American Heart Association, 2009, 119 (18), pp.2426-34. 〈10.1161/CIRCULATIONAHA.108.829267〉 |
| ISSN: | 0009-7322 1524-4539 |
| DOI: | 10.1161/CIRCULATIONAHA.108.829267⟩ |
| Popis: | Background— The pathophysiological background of catecholaminergic polymorphic ventricular tachycardia is well understood, but the clinical features of this stress-induced arrhythmic disorder, especially the incidence and risk factors of arrhythmic events, have not been fully ascertained. Methods and Results— The outcome in 101 catecholaminergic polymorphic ventricular tachycardia patients, including 50 probands, was analyzed. During a mean follow-up of 7.9 years, cardiac events defined as syncope, aborted cardiac arrest, including appropriate discharges from implantable defibrillators, or sudden cardiac death occurred in 27 patients, including 2 mutation carriers with normal exercise tests. The estimated 8-year event rate was 32% in the total population and 27% and 58% in the patients with and without β-blockers, respectively. Absence of β-blockers (hazard ratio [HR], 5.48; 95% CI, 1.80 to 16.68) and younger age at diagnosis (HR, 0.54 per decade; 95% CI, 0.33 to 0.89) were independent predictors. Fatal or near-fatal events defined as aborted cardiac arrest or sudden cardiac death occurred in 13 patients, resulting in an estimated 8-year event rate of 13%. Absence of β-blockers (HR, 5.54; 95% CI, 1.17 to 26.15) and history of aborted cardiac arrest (HR, 13.01; 95% CI, 2.48 to 68.21) were independent predictors. No difference was observed in cardiac and fatal or near-fatal event rates between probands and family members. Conclusions— Cardiac and fatal or near-fatal events were not rare in both catecholaminergic polymorphic ventricular tachycardia probands and affected family members during the long-term follow-up, even while taking β-blockers, which was associated with a lower event rate. Further studies evaluating concomitant therapies are necessary to improve outcome in these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|